Table 1. Baseline characteristics of the patients in the durvalumab plus chemotherapy (durvalumab) versus atezolizumab plus chemotherapy (atezolizumab) groups.

Characteristics	Durvalumab (N=100)	Atezolizumab (N=43)	P
Median age [range], years	61 [23–82]	64 [43–81]	0.54
Age group, n [%]			0.9
<65 years	57 [57]	24 [56]
≥65 years	43 [43]	19 [44]
Sex, n [%]			0.3
Men	72 [72]	29 [67]
Women	28 [28]	14 [33]
ECOG performance status, n [%]			0.83
≤1	94 [94]	40 [94]
≥2	6 [6]	3 [6]
Smoking status, n [%]			0.27
Never	60 [60]	27 [63]
Current	33 [33]	10 [23]
Former	7 [7]	6 [14]
Disease stage at initiation of immunotherapy, n [%]			0.13
Limited stage	10 [10]	9 [21]
Extensive stage	90 [90]	34 [79]
Brain or central nervous system metastasis, n [%]			0.37
Yes	23 [23]	7 [16]
No	77 [77]	36 [83]
Liver metastases, n [%]
Yes	14 [14]	5 [12]	0.7
No	86 [86]	38 [88]
Bone metastases, n [%]			0.08
Yes	33 [33]	8 [19]
No	67 [67]	35 [81]
Radiotherapy, n [%]			0.06
Yes	42 [42]	32 [74]
No	58 [58]	11 [26]
Brain radiotherapy, n [%]			0.07
Yes	22 [22]	4 [9]
No	78 [78]	39 [91]
Immunotherapy at the first line, n [%]			0.14
Yes	71 [71]	29 [67]
No	29 [29]	14 [33]

ECOG, Eastern Cooperative Oncology Group.